在肿瘤治疗中，相比于化疗药物，近年来生物制药日新月异，尤其是以单克隆抗体为代表的创新药已广泛应用于临床，比如大家耳熟能详的贝伐珠单抗，曲妥珠单抗，帕博利珠单抗等。由于大部分临床医生，不熟悉免疫基础知识，在学术交流中，单克隆抗体抗癌机制部分，令人费解的 ...

Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that ...

Immune response to SARS-CoV-2: B-lymphocyte releases antibodies that bind to and mark coronaviruses. ... More Hence, the viruses can't penetrate into their target cells and are engulfed and ...

Incyte INCY announced that the FDA has approved its humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, ...

Creative Biolabs recently rolled out a three-dimensional upgrade designed to make antibodies safer, more potent, and easier to develop. SHIRLEY, NY, UNITED STATES, June 18, 2025 /EINPresswire.com/ -- ...

AGEN-1721 was designed as an Fc-enhanced bifunctional antibody to selectively target FAP and neutralize TGF-β via an optimized TGF-βR2 TRAP moiety fused to an engineered Fc region, with the aim of ...

Once hailed as the future of immuno-oncology, it’s been a tough few months for any remaining fans of anti-TIGIT antibodies. | ...

Treated recipients received either 3 mg/kg rapamycin intraperitoneally for the first 14 d after transplantation (days 0-13) and/or 0.25 mg/dose CD40L-specific antibody (days 0, 2, 4, 7 and 10 ...

Broad method of use patent protection for COM902, a potential best-in-class reduced Fc, clinical stage, anti-TIGIT antibody, in triple combination with any anti-PD-1 antibody and any anti-PVRIG ...